LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:46 am
Share
LegoChem Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 5,218.65 million compared to KRW 6,391.19 million a year ago. Net loss was KRW 19,765.16 million compared to KRW 8,496.28 million a year ago. Basic loss per share from continuing operations was KRW 746 compared to KRW 135 a year ago. Diluted loss per share from continuing operations was KRW 746 compared to KRW 135 a year ago. Basic loss per share was KRW 746 compared to KRW 135 a year ago.
For the nine months, negative sales was KRW 0.0004 million compared to KRW 0.00029 million a year ago. Net loss was KRW 57,551.95 million compared to KRW 19,590.62 million a year ago. Basic loss per share from continuing operations was KRW 2,179 compared to KRW 807 a year ago. Diluted loss per share from continuing operations was KRW 2,179 compared to KRW 807 a year ago. Basic loss per share was KRW 2,179 compared to KRW 807 a year ago.
LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.